Aug 2026· Biomaterials Advances· Vol 189, pp.
215116
· 0 citations· 31 references
Medicine
TL;DR
This platform integrates material design with cellular immunoengineering to overcome a key barrier in post-radiation immunity, presenting a versatile strategy to enhance dendritic cell function and synergize with radiotherapeutic modalities for more durable antitumor immunity.
Abstract
Radiotherapy initiates an antitumor immune response by releasing tumor antigens; however, its efficacy is often limited by the subsequent quantitative and qualitative dysfunction of dendritic cells within the tumor microenvironment. This dysfunction leads to impaired antigen presentation and suboptimal T cell activation. To address this, we developed a biomaterial-based cellular engineering strategy using silk fibroin-based dendritic cell backpacks. Silk fibroin backpacks offer structural stability and aqueous processability, enabling the incorporation of CpG under mild conditions. The easy functionalization of silk fibroin allows hydrophobic modifications on the backpack surface, enabling covalent grafting of hydrophobic chains onto the BP surface and promoting stable association with the DC membrane through hydrophobic intercalation. These backpacks preserve dendritic cell function while providing sustained local delivery of immune signals. This platform integrates material design with cellular immunoengineering to overcome a key barrier in post-radiation immunity, presenting a versatile strategy to enhance dendritic cell function and synergize with radiotherapeutic modalities for more durable antitumor immunity.
Therapeutic tumor vaccinations are promising for cancer immunotherapy. However, challenges like inadequate antigen encapsulation, weak immune activation, and an immunosuppressive tumor microenvironment limit their efficacy. To overcome these, an injectable Nano-in-Gel vaccine composed of porcine lung-derived extracellu...
Jie Wu, Xin-Xin Bu, Zi Liu et al.· International Journal of Pha...· 0 citations
Personalized cancer vaccines show great promise in targeting tumors with immunity; however, obstacles to their widespread use in clinical practice remain, including difficulties in identifying neoantigens, slow antigen clearance, and inadequate removal of tumor cells expressing the antigen. Here, we present a hydrogel...
Xiao-Ya Wang, Da-Xiu Deng, Yi-Xi He et al.· International Immunopharmaco...· 0 citations
Adoptive cell therapy continues to encounter diverse hurdles in treating solid tumors, including poor infiltration, an immunosuppressive microenvironment, and tumor immune evasion, necessitating the endowment of effector cells with multiple functionalities. However, conventional cell-engineering techniques, including g...
Qing-Guo Zhong, Yu-Xin Huang, Zhen-Hua Li et al.· BME Horizon· 0 citations
Whole tumor cell vaccines are uniquely positioned for personalized immunotherapy by presenting the full repertoire of tumor-associated antigens to counter tumor heterogeneity, yet their translation is persistently hindered by poor immunogenicity and the requirement for multiple administrations. Herein, we introduce a s...
Hong-Ze Ren, Qing-Ying Wu, Wei Yang et al.· Angewandte Chemie· 0 citations
BACKGROUND
Cancer immunotherapy has shown considerable promise, particularly through dendritic cell (DC)-based vaccines, which are capable of inducing potent, durable, and tumor-specific immune responses. However, their clinical efficacy remains limited by the immature phenotype of DCs, inefficient antigen presentation...
Atefeh Eteghadi, N. Taghipour, S. Hosseinzadeh et al.· Biochemical and Biophysical...· 0 citations
Adjuvant immune checkpoint inhibitor (AICI) therapy is limited by inadequate durable immunological memory against tumor recurrence and metastasis. Herein, we present a metalloimmunological hydrogel-based and innate immunity-focused cancer vaccine (IT-Vax) that synergizes innate-adaptive crosstalk to potentiate AICI eff...
Tao He, Xiao-Rong Kou, Ye Sang et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.